File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: Meta-analysis

TitleTranscatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: Meta-analysis
Authors
KeywordsMeta-analysis
Chinese herbal therapy
Systematic review
Hepatocellular carcinoma
Transcatheter arterial chemoembolization
Traditional Chinese medicine
Issue Date2009
Citation
Expert Opinion on Investigational Drugs, 2009, v. 18, n. 5, p. 617-635 How to Cite?
AbstractObjective: Chinese herbal therapy is sometimes used in conjunction with transcatheter arterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) in Asian countries. This study aims to systemically review the efficacy of Chinese herbal therapy in HCC patients receiving TACE. Methods: Meta-analysis was performed for clinical trials comparing Chinese herbal therapy versus no Chinese herbal therapy given to HCC patients receiving TACE. Publications in 10 electronic databases were extensively searched. Results/conclusion: Chinese herbal therapy was associated with a significant rise in the number of patients with survival > 1-year, 2-year and 3-year, as well as a significant rise in the number of patients who reported complete or partial response and non-deterioration performance status. Chinese herbal therapy also showed significant efficacies in the increase of T cells and natural killer cells, whereas a significant lower blood α-fetoprotein concentration was reported. There were a significant increase in white blood cell count, significant lower risk in patients with nausea and vomiting, and a significant rise in patients with increased body weight when Chinese herbal therapy was given. The evidence from this review supports the use of Chinese herbal therapy to enhance the efficacy of TACE in HCC patients. However, owing to limited data and heterogeneity of the included studies, further trials are required. © 2009 Informa UK Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/199980
ISSN
2015 Impact Factor: 4.408
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCho, Williamcs-
dc.contributor.authorChen, Hai-Yong-
dc.date.accessioned2014-07-26T23:10:59Z-
dc.date.available2014-07-26T23:10:59Z-
dc.date.issued2009-
dc.identifier.citationExpert Opinion on Investigational Drugs, 2009, v. 18, n. 5, p. 617-635-
dc.identifier.issn1354-3784-
dc.identifier.urihttp://hdl.handle.net/10722/199980-
dc.description.abstractObjective: Chinese herbal therapy is sometimes used in conjunction with transcatheter arterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) in Asian countries. This study aims to systemically review the efficacy of Chinese herbal therapy in HCC patients receiving TACE. Methods: Meta-analysis was performed for clinical trials comparing Chinese herbal therapy versus no Chinese herbal therapy given to HCC patients receiving TACE. Publications in 10 electronic databases were extensively searched. Results/conclusion: Chinese herbal therapy was associated with a significant rise in the number of patients with survival > 1-year, 2-year and 3-year, as well as a significant rise in the number of patients who reported complete or partial response and non-deterioration performance status. Chinese herbal therapy also showed significant efficacies in the increase of T cells and natural killer cells, whereas a significant lower blood α-fetoprotein concentration was reported. There were a significant increase in white blood cell count, significant lower risk in patients with nausea and vomiting, and a significant rise in patients with increased body weight when Chinese herbal therapy was given. The evidence from this review supports the use of Chinese herbal therapy to enhance the efficacy of TACE in HCC patients. However, owing to limited data and heterogeneity of the included studies, further trials are required. © 2009 Informa UK Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofExpert Opinion on Investigational Drugs-
dc.subjectMeta-analysis-
dc.subjectChinese herbal therapy-
dc.subjectSystematic review-
dc.subjectHepatocellular carcinoma-
dc.subjectTranscatheter arterial chemoembolization-
dc.subjectTraditional Chinese medicine-
dc.titleTranscatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: Meta-analysis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/13543780902855308-
dc.identifier.pmid19388879-
dc.identifier.scopuseid_2-s2.0-67649595227-
dc.identifier.volume18-
dc.identifier.issue5-
dc.identifier.spage617-
dc.identifier.epage635-
dc.identifier.isiWOS:000266191900007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats